State Street Corp increased its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 8.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 999,012 shares of the medical research company’s stock after purchasing an additional 74,751 shares during the period. State Street Corp owned 1.26% of NeoGenomics worth $8,953,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the stock. Wrapmanager Inc. bought a new stake in shares of NeoGenomics during the second quarter worth approximately $109,000. KCG Holdings Inc. acquired a new stake in shares of NeoGenomics in the first quarter valued at approximately $118,000. Parkwood LLC acquired a new stake in shares of NeoGenomics in the second quarter valued at approximately $165,000. Principal Financial Group Inc. raised its position in shares of NeoGenomics by 2.5% in the first quarter. Principal Financial Group Inc. now owns 22,164 shares of the medical research company’s stock valued at $175,000 after buying an additional 545 shares in the last quarter. Finally, Voya Investment Management LLC raised its position in shares of NeoGenomics by 15.4% in the second quarter. Voya Investment Management LLC now owns 29,333 shares of the medical research company’s stock valued at $263,000 after buying an additional 3,921 shares in the last quarter. Institutional investors and hedge funds own 83.73% of the company’s stock.
NeoGenomics, Inc. (NASDAQ:NEO) opened at $9.15 on Friday. The stock has a market cap of $740.57, a price-to-earnings ratio of 184.20, a PEG ratio of 11.51 and a beta of 0.85. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.99 and a current ratio of 2.14. NeoGenomics, Inc. has a 1-year low of $7.12 and a 1-year high of $11.63.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $63.05 million during the quarter, compared to the consensus estimate of $63.11 million. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.97%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.04 earnings per share. research analysts predict that NeoGenomics, Inc. will post 0.04 EPS for the current fiscal year.
A number of research firms have recently weighed in on NEO. BidaskClub upgraded shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 23rd. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Janney Montgomery Scott restated a “buy” rating on shares of NeoGenomics in a research report on Thursday, October 26th. BTIG Research downgraded shares of NeoGenomics from a “buy” rating to a “neutral” rating in a research report on Monday, September 11th. Finally, Gabelli assumed coverage on shares of NeoGenomics in a research report on Thursday, August 24th. They set a “buy” rating and a $9.00 price objective for the company. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.33.
ILLEGAL ACTIVITY WARNING: “State Street Corp Has $8.95 Million Position in NeoGenomics, Inc. (NASDAQ:NEO)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/08/state-street-corp-increases-stake-in-neogenomics-inc-neo.html.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.